Skip to main content

Table 4 Synoptic review of randomized controlled trials and real-life experiences using erenumab as a preventive treatment for migraine

From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Study Study design Type of patients Preventive medications Previous treatment failures Main findings for erenumab compared with controls
Tepper et al. (2017) NCT02066415 [49] Randomized, double-blind, placebo-controlled, phase 2 trial Chronic migraine Not allowed < 3 (no response) MMD reduced by 6.6 days vs. 4.2 days with placebo. 40% vs. 41% in the erenumab 70 mg vs. 140 mg groups achieved a > 50% reduction
Dodick et al. (2018)
ARISE [50]
Randomized, double-blind, placebo-controlled, phase 3 study Episodic migraine Allowed < 2 (no response) MMD reduced by 2.9 days vs. 1.8 days with placebo. 39.7% of erenumab recipients achieved ≥50% reduction
Goadsby et al. 2017
STRIVE [51]
Randomized, double-blind, placebo-controlled, phase 3 study Episodic migraine Allowed (< 2) < 2 (no response) MMD reduced by 3.2 vs. days in the erenumab 70 mg vs. 140 mg group, and by 1.8 days with placebo. 43.3%, 50.0%, and 26.6%, respectively, achieved a ≥ 50% reduction in MMD
Ashina et al. (2018) [52] Randomized, double-blind, placebo-controlled study with subgroup analyses Chronic migraine Not allowed 0, ≥1, ≥2 (no response) Reduction in MMD vs. placebo for erenumab 70 mg vs. 140 mg: No prior treatment failure, 2.2 vs. 0.5 days; ≥1 prior failed medication category subgroup, 2.5 vs. 3.3 days; ≥2 prior failed medication categories, 2.7 vs. 4.3 days
Reuter et al. (2018) LIBERTY [48] Randomized, double-blind, placebo-controlled, phase 3b study Episodic migraine Not allowed Failure of 2–4 prior preventive treatments MMD reduced by > 50% in 30% of patients
Barbanti et al. (2019) [18] Real-life data Episodic and chronic migraine Allowed Failure of 4–6 prior preventive treatments ≥50% reduction of MMD at weeks 4 and 8, respectively, in 68.2% and 87.5% of chronic patients and 50% and 100% of episodic patients
Ornello et al. (2020) [19] Real-life data Episodic and chronic migraine Allowed Failure of ≥2 prior preventive treatments MMD reduced from a mean of 19 days to 4 days. MMD reduced by > 50% in 70% of patients
Raffaelli et al. (2020) [20] Retrospective real-life Chronic migraine Not specified Failure of 5 prior preventive treatments plus onabotulinumtoxinA MHD reduction of 3.7 days after the first treatment and 4.7 days after 3 treatment cycles
Robbins et al. (2020) [53] Retrospective real-life Chronic migraine Allowed Failure of ≥3 prior preventive treatments MMD reduced by > 30% in 43% of patients
  1. MHD monthly headache days, MMD monthly migraine days, vs. versus
\